Skip to main content

Interleukin Genetics Inks $1.2M Research Agreement with ABG

NEW YORK (GenomeWeb News) — Interleukin Genetics has signed a $1.2 million research agreement with Alticor subsidiary Access Business Group International to search for genetic variations in four main disease areas: osteoporosis, cardiovascular disease, nutrigenomics, and dermagenomics.
Under the terms of the agreement, Interleukin will conduct studies to correlate SNPs with the risk of osteoporosis or cardiovascular disease in Asian populations, and will also conduct additional studies in North American populations to identify genetic factors that influence skin appearance and athletic performance in response to nutritional products.
The company said that around $800,000 of unspent funding from earlier research pacts with Alticor will be credited against the costs of the ABG agreement.
This is the eighth research agreement between Interleukin Genetics and Alticor. Earlier agreements led to the commercialization of a proprietary genetic test for the risk of early heart disease, a nutritional supplement for those testing positive for the heart risk factor, as well as a general nutrition test panel.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.